Literature DB >> 2856900

Kinetic determination of blood coagulation Factor XIII in plasma.

L Muszbek, J Polgár, L Fésüs.   

Abstract

We have designed a new kinetic assay for estimating Factor XIII in plasma. Plasma fibrinogen is removed by treatment with bentonite (colloidal aluminum silicate) before measurement. During the lag phase, Factor XIII is transformed by thrombin and Ca2+ into active transglutaminase (EC 2.3.2.13), which attaches the substrate ethylamine to a glutamine residue in acetylated, dephosphorylated beta-casein. During the reaction, ammonia is released, which can be continuously monitored in an NADPH-dependent indicator reaction catalyzed by glutamate dehydrogenase (EC 1.4.1.4). We determined the optimal concentrations of substrate and activator and found that, to eliminate the clottable fibrinogen from the plasma samples, bentonite treatment was more advantageous than the traditional heat treatment. Results by the method correlate well with those by the most widely used amine incorporation and immunoinhibition assays for Factor XIII. We established a reference interval of 12.1-22.7 U/L; at optimal conditions, the variance of the method was less than 3% within this range. The method has several theoretical and practical advantages over traditional determinations of Factor XIII.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2856900

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  6 in total

1.  Tridegin, a new peptidic inhibitor of factor XIIIa, from the blood-sucking leech Haementeria ghilianii.

Authors:  S Finney; L Seale; R T Sawyer; R B Wallis
Journal:  Biochem J       Date:  1997-06-15       Impact factor: 3.857

2.  Recombinant factor XIII improves established experimental colitis in rats.

Authors:  G D'Argenio; A Grossman; V Cosenza; N D Valle; G Mazzacca; P D Bishop
Journal:  Dig Dis Sci       Date:  2000-05       Impact factor: 3.199

3.  Catalytic mechanism and three-dimensional structure of adenine deaminase.

Authors:  Siddhesh S Kamat; Ashima Bagaria; Desigan Kumaran; Gregory P Holmes-Hampton; Hao Fan; Andrej Sali; J Michael Sauder; Stephen K Burley; Paul A Lindahl; Subramanyam Swaminathan; Frank M Raushel
Journal:  Biochemistry       Date:  2011-02-04       Impact factor: 3.162

4.  Differential expression of multiple transglutaminases in human colon: impaired keratinocyte transglutaminase expression in ulcerative colitis.

Authors:  G D'Argenio; M Calvani; N Della Valle; V Cosenza; G Di Matteo; P Giorgio; S Margarucci; O Petillo; F P Jori; U Galderisi; G Peluso
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

5.  Non-proteolytic activation of cellular protransglutaminase (placenta macrophage factor XIII).

Authors:  J Polgár; V Hidasi; L Muszbek
Journal:  Biochem J       Date:  1990-04-15       Impact factor: 3.857

6.  New developments in the management of congenital Factor XIII deficiency.

Authors:  Zehra Fadoo; Quratulain Merchant; Karim Abdur Rehman
Journal:  J Blood Med       Date:  2013-05-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.